Abstract
Introduction Molnupiravir (MNP) is an orally administered prodrug which prevents disease progression in patients at high risk for severe COVID-19. We conducted a real-life case-control study on a cohort of outpatients, with Omicron SARS-CoV-2 infection to assess the effectiveness of MNP in reducing the occurrence of hospital admission, admission in intensive care unit (ICU) and death at day 28.
Materials and methods Cases were enrolled among SARS-CoV-2 positive subjects that sought medical care during the first five days of symptoms from January 1st, 2022, to December 31st, 2022, and received MNP. Control participants were selected from a regional database among those who tested positive during the study period and did not receive antiviral treatment for SARS-CoV-2.
Results 1382 patients were included (cases: 146, controls: 1236). Vaccinated patients showed lower risk of mortality and composite outcome (at least one among hospital admission, admission in ICU and all-cause death) compared to unvaccinated ones (0.6% vs 7.8%, p<0.001 and 2% vs 7.8%, p=0.001 respectively). After full-matching propensity score, MNP-treated subjects showed a lower incidence of composite outcome, while no effect was observed on the single outcomes. In the subgroup analysis according to the vaccination status, MNP proved effective in preventing all the outcomes among unvaccinated patients, while showed to reduce the risk of ICU admission both in vaccinated and unvaccinated patients.
Conclusions Treatment with MNP proved effective in reducing the risk of composite outcome among outpatients with SARS-CoV-2 infection. The beneficial effect of MNP treatment in reducing progression is more pronounced in unvaccinated patients.
Competing Interest Statement
Prof. IVAN GENTILE reports personal fees from MSD, AbbVie, Gilead, Pfizer, GSK, SOBI, Nordic/Infecto Pharm, Angelini and Abbott, as well as departmental grants from Gilead and support for attending a meeting from Janssen, outside the submitted work. All other authors have no competing interests to declare
Funding Statement
This study was funded by the Campania Region as part of the European Fund for Regional Development (Fondo Europeo Sviluppo Regionale, FESR) for 2014-2020, under the project titled "Impact of Early Anti-SARS-CoV-2 Treatment in Vaccinated Subjects on Clinical Progression and Onset of Long-COVID (SAVALO Study)". The funds received have been utilized to engage nursing staff who were responsible for conducting telephone interviews with control participants who opted to participate, and for collecting data on paper-based Case Report Forms (CRFs). The funds will also be allocated for publication charges, if necessary.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the ethics committee "Comitato Etico Università Federico II-A.O.R.N. A. Cardarelli" (protocol number 0015191, 22nd March 2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵° Federico II COVID Team is listed in the acknowledgement
Data Availability
The datasets generated and/or analysed during the current study, along with the studys Case Report Forms (CRFs), the written informed consent from case participants, and the records of the telephonic interviews conducted with control participants, including their verbal informed consent, are stored by the studys data manager at the Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. These can be retrieved and reviewed upon request by any relevant authority.